Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2745 | Oxygen-ozone therapy, probiotic supplementation and Standard of care Wiki | 0.58 |
| drug1856 | IMM-101 Wiki | 0.58 |
| drug3638 | SivoMixx (200 billion) Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020521 | Stroke NIH | 0.14 |
| D011024 | Pneumonia, Viral NIH | 0.07 |
| D011014 | Pneumonia NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001297 | Stroke HPO | 0.14 |
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 3 clinical trials
COVID-19 has a big impact on individuals and society as a whole. Especially persons with (multiple) comorbidities such as stroke are affected. The impact of COVID-19 on stroke rehabilitation delivery and stroke patients' functioning is unclear.
Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions
Measure: Rehabilitation data Time: 3 month after start lockdownDescription: Patient-reported upper limb use in daily life
Measure: Motor Activity Log - 14 Item Version Time: 3 month after start lockdownDescription: Patient-reported engagement in physical activity in daily life
Measure: International Physical Activity Questionnaire Time: 3 month after start lockdownDescription: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity
Measure: Patient-Reported Outcomes Measurement Information System - 29 Version Time: 3 month after start lockdownDescription: Patient-reported global rating of physical activity engagement and upper limb use in daily life
Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use) Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities
Measure: Fatigue Severity Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Depression and anxiety
Measure: Hospital Anxiety and Depression Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Assesses cognitive functions
Measure: Montreal Cognitive Assessment Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account
Measure: Functional Ambulation Categories Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Gait speed and cadence
Measure: Ten-Meter Walk Test Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs
Measure: Rivermead Mobility Index Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks
Measure: Activities-specific Balance Confidence Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Upper and lower limb motor function
Measure: Fugl-Meyer Motor Assessment Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Upper limb capacity
Measure: Action Research Arm Test Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Global disability
Measure: modified Rankin Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Neurological impairments
Measure: National Institutes of Health Stroke Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions
Measure: Rehabilitation data Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-reported upper limb use in daily life
Measure: Motor Activity Log - 14 Item Version Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-reported engagement in physical activity in daily life
Measure: International Physical Activity Questionnaire Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity
Measure: Patient-Reported Outcomes Measurement Information System - 29 Version Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownThe purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.
Description: WHO definition of "influenza-like illness" (ILI) [Fitzner 2018] or confirmed viral/bacterial respiratory infection AND Results in a change or delay in cancer treatment or requirement for and unscheduled medical assesment, hospitalization or death.
Measure: The rate of "flu-like illness" which includes: Time: 1 yearNeurologic, neuropsychological and neuropsychiatric symptoms, signs and diagnoses are increasingly being reported in COVID-19 patients. However, the extent and implications of such "NeuroCOVID" involvement, as well as blood and MRI biomarkers for neurological and psychiatric COVID-19-affection and treatments, warrants further studies. The investigator will perform a national study with clinical and biomarker assessments of NeuroCOVID in approximately 150 Norwegian patients, recruited from ongoing COVID-studies in Norway as well as from neurological departments in Norway. The investigator will define the burden of neurological, psychological and psychiatric complications of COVID-19 disease and identify clinical characteristics and biomarkers for both short- and long-term neurological treatment and rehabilitation. Blood samples for biomarker analyses, brain MRI, clinical neurological, neurophysiological and neuropsychological assessments will be performed at 6 and 12 moths after acute disease,
Description: Rate of neurological manifestations of COVID-19
Measure: Rate of peripheral and central nervous affection Time: 6 monthsDescription: Rate of neurological manifestations of COVID-19
Measure: Rate of peripheral and central nervous affection Time: 12 monthsDescription: Rate of psychiatric disorders as manifestations of COVID-19
Measure: Rate of psychiatric disorders at 6-months follow-up Time: 6 monthsDescription: Rate of psychiatric disorders as manifestations of COVID-19
Measure: Rate of psychiatric disorders at 12-months follow-up Time: 12 monthsDescription: Neuropsychological function at 6-months follow up months after COVID-19. MoCA with score > 18 are eligible to further testing. Neuropsychological testing cover the most important domains of cognitive function enabling valid test data across different functional domains
Measure: Neuropsychological function at 6-months follow up Time: 6 monthsDescription: Neuropsychological function at 12-months follow up months after COVID-19. When MoCA > 18 at 6 months, MoCA is not done at 12 months. Neuropsychological testing cover the most important domains of cognitive function enabling valid test data across different functional domains.
Measure: Neuropsychological function at 12-months follow up and change in function from 6 to 12 months. Time: 12 monthsDescription: Rate of stroke
Measure: Rate of stroke at 6-months follow up Time: 6 monthsDescription: Rate of stroke
Measure: Rate of stroke at 12-months follow up Time: 12 monthsDescription: Rate of death
Measure: Rate of death at 6-months follow-up Time: 6 monthsDescription: Rate of death
Measure: Rate of death at 12-months follow-up Time: 12 monthsDescription: Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography
Measure: Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 6-months follow-up Time: 6 monthsDescription: Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography
Measure: Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 12-months follow-up Time: 12 monthsDescription: Rate of myopathy
Measure: Rate of myopathy at 6-months follow-up Time: 6 monthsDescription: Rate of myopathy
Measure: Rate of myopathy at 12-months follow-up Time: 12 monthsDescription: Rate of brain MRI pathology
Measure: Rate of brain MRI pathology at 6-months follow-up Time: 6 monthsDescription: Rate of brain MRI pathology
Measure: Rate of brain MRI pathology at 12-months follow-up Time: 12 monthsDescription: Levels of serum eurofilaments
Measure: Levels of serum neurofilaments at 6-months follow-up Time: 6 monthsDescription: Levels of serum neurofilaments
Measure: Levels of serum neurofilaments at 12-months follow-up Time: 12 monthsDescription: Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms
Measure: Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 6-months follow-up Time: 6 monthsDescription: Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms
Measure: Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 12-months follow-up Time: 12 monthsDescription: Duration of hospital and rehabilitation stay at 6-months follow up
Measure: Duration of hospital and rehabilitation stay Time: 6 monthsDescription: Duration of hospital and rehabilitation stay at 12-months follow up
Measure: Duration of hospital and rehabilitation stay Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports